Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Recursion Pharmaceuticals focuses on innovative drug discovery with a streamlined R&D pipeline in oncology and rare diseases.

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. | Recursion is ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...

Retail sentiment toward Recursion Pharmaceuticals (RXRX) leaned bearish ahead of its first-quarter earnings on Monday, as ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.